NMN/NR (Nicotinamide Mononucleotide/Riboside) and PPIs (Omeprazole, Pantoprazole): Drug Interaction Guide

What Is the Actual Interaction Risk Between NMN/NR and PPIs?

The direct interaction risk between NMN or NR and proton pump inhibitors is low. Neither the FDA label for omeprazole (Prilosec) nor the FDA label for pantoprazole (Protonix) lists nicotinamide mononucleotide or nicotinamide riboside as interacting agents. NMN and NR are dietary supplements metabolized through the NAD+ biosynthesis pathway, not through hepatic CYP enzymes in any clinically significant way.

One indirect mechanism deserves attention: gastric acid suppression.

How PPIs Change the Stomach Environment

Omeprazole 20-40 mg daily raises mean intragastric pH from roughly 1.5-2.5 to above 4.0, often sustaining pH 4-6 for 12-18 hours per dose. Pantoprazole 40 mg achieves a similar pH profile. This matters because NMN is a mildly acid-labile molecule. In acidic conditions (pH <3), NMN can undergo partial hydrolysis to nicotinamide and ribose-5-phosphate before absorption. When a PPI raises gastric pH toward neutral, that degradation pathway is reduced, which could theoretically increase or alter NMN bioavailability rather than decrease it.

NR Follows a Different Route

Nicotinamide riboside is absorbed primarily through concentrative nucleoside transporters (CNT1/CNT2) and equilibrative nucleoside transporters (ENT1/ENT2) in the small intestinal epithelium. These transporters are not regulated by luminal pH in a clinically meaningful way. PPI-driven pH changes are therefore less likely to affect NR absorption than NMN absorption.

Pharmacokinetics: CYP Enzymes, P-gp, and Where NMN/NR Fit

Understanding whether two agents interact pharmacokinetically requires checking three channels: cytochrome P450 enzyme competition, P-glycoprotein (P-gp) transporter competition, and shared protein binding.

CYP2C19 and CYP3A4, PPIs Are Substrates, NMN/NR Are Not

Omeprazole is primarily a CYP2C19 substrate and a moderate CYP2C19 inhibitor, with secondary metabolism via CYP3A4. Pantoprazole is also a CYP2C19 substrate but carries a lower CYP2C19 inhibition signal than omeprazole. This is why omeprazole, but not pantoprazole, carries a warning against co-administration with clopidogrel, a warning based on reduced clopidogrel activation, not anything related to supplements.

NMN is phosphorylated intracellularly to NMN and then to NAD+ through the NAMPT and NMNAT enzyme pathways. Neither NMN nor its immediate metabolites are processed by CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at pharmacologically relevant concentrations. NR follows the NRK1/NRK2 phosphorylation route to NMN and then to NAD+. The same CYP independence applies.

There is no competitive substrate relationship. The two drug classes do not fight for the same enzyme.

P-gp: No Evidence of Interaction

P-glycoprotein (MDR1/ABCB1) is an efflux transporter that limits intestinal absorption of many drugs. Omeprazole is a weak P-gp substrate. Pantoprazole has minimal P-gp involvement. NMN and NR have no published data demonstrating P-gp substrate or inhibitor activity. Without shared P-gp kinetics, no transporter-mediated interaction is expected.

Protein Binding

Omeprazole is approximately 95% plasma protein-bound. Pantoprazole is approximately 98% protein-bound. NMN in plasma is rapidly converted to NMN and enters cells; its free-fraction kinetics differ entirely from a protein-bound small molecule. Displacement interactions require competition for the same binding sites, which does not apply here.

Clinical Evidence for NMN and NR Absorption and Efficacy

Before advising patients whether a PPI meaningfully affects NMN or NR outcomes, it helps to know what the clinical evidence actually says about NMN/NR bioavailability in healthy adults.

Key NMN Trials

A randomized, placebo-controlled trial published in 2023 (N=80 healthy adults, age 40-65) tested oral NMN 250 mg/day versus 500 mg/day versus placebo for 10 weeks. Both doses significantly raised whole-blood NAD+ concentrations: the 250 mg group saw a 38% rise and the 500 mg group saw a 55% rise versus baseline, P<0.001. No gastric co-medications were tracked as covariates in that study, so direct PPI impact on NAD+ response cannot be extracted from the data.

An earlier first-in-human pharmacokinetic study (N=10 healthy men) by Irie et al. (2020) showed that a single 100 mg, 250 mg, or 500 mg oral dose of NMN produced dose-dependent rises in blood NMN, NAD+, and downstream metabolites within 2-3 hours. The study confirmed oral bioavailability without any acid-suppression context, establishing a pharmacokinetic baseline.

Key NR Trials

Trammell et al. (2016) published the first controlled human NR pharmacokinetics study (N=12), demonstrating that a single 1,000 mg oral dose of NR raised blood NAD+ metabolites within 2-4 hours and that the rise was sustained at 24 hours. A subsequent 6-week trial by Martens et al. (2018) in 24 healthy older adults showed that NR 1,000 mg/day raised whole-blood NAD+ by approximately 60% versus placebo. Neither trial excluded PPI users or stratified results by gastric pH, which is a gap in the current evidence base.

The table below organizes current evidence by interaction mechanism for clinical decision-making.

| Mechanism | PPIs Involved? | NMN/NR Involved? | Clinical Risk | |---|---|---|---| | CYP2C19 substrate competition | Yes (omeprazole, pantoprazole) | No | None | | CYP3A4 substrate competition | Partial (omeprazole) | No | None | | P-gp efflux transporter | Weak (omeprazole) | No evidence | None | | Gastric pH / dissolution | Yes (raises pH to 4-6) | NMN: mild acid lability; NR: pH-independent | Theoretical, unquantified | | Protein binding displacement | High binding (both PPIs) | Not applicable to NMN/NR | None | | NAD+ pathway pharmacodynamics | No direct PD effect | Core mechanism | No PD interaction |

Pharmacodynamic Interaction: Does PPI Use Affect NAD+ Biology?

Pharmacodynamic interactions happen when two agents affect the same biological target in additive, antagonistic, or synergistic ways. PPIs work on the H+/K+ ATPase proton pump in gastric parietal cells. NMN and NR replenish NAD+, a coenzyme involved in over 500 enzymatic reactions including SIRT1/SIRT3 sirtuin deacetylase activity, PARP1 DNA repair, and NNMT methylation.

These targets do not overlap. Acid suppression and NAD+ repletion operate through entirely separate signaling pathways. No pharmacodynamic antagonism or potentiation is expected.

One Nuance Worth Raising: B12 and Magnesium

Long-term PPI use (longer than 1 year) is associated with reduced vitamin B12 absorption and hypomagnesemia, both documented in FDA Drug Safety Communication (2011) and confirmed in a meta-analysis of Lam et al. (2013). This is not an NMN/NR interaction, but patients combining NAD+ precursors with long-term PPI therapy may already be pursuing healthy aging strategies. Checking B12 and magnesium levels annually in that population is sensible clinical practice.

Dosing and Timing Recommendations

Practical guidance does not require a detected interaction to be useful. Even theoretical pH-mediated dissolution changes can be minimized with simple timing adjustments.

Timing NMN/NR Around PPI Doses

PPIs are most effective when taken 30-60 minutes before a meal, which is when acid suppression peaks. NMN and NR taken on an empty stomach before the PPI dose would encounter whatever residual gastric acidity remains from overnight, before the PPI has fully suppressed acid for the day.

A practical protocol:

1. Take NMN or NR with a small glass of water on an empty stomach.
2. Wait 30 minutes.
3. Take the PPI as prescribed, then eat breakfast.

This sequence ensures NMN or NR passes through the stomach under near-baseline acid conditions, then the PPI achieves its intended acid suppression for the meal. No dose adjustment of either agent is warranted.

Standard Dosing Reference Points

• NMN: 250-500 mg/day orally is the range used in published clinical trials. Doses up to 1,200 mg/day for 4 weeks showed no adverse effects in a safety study (N=10).
• NR: 1,000 mg/day was used in the Martens et al. 6-week RCT. Commercial products typically offer 250-500 mg doses.
• Omeprazole: 20-40 mg once daily, taken 30-60 minutes before first meal per FDA label.
• Pantoprazole: 40 mg once daily, taken 30-60 minutes before first meal per FDA label.

Special Populations

CYP2C19 Poor Metabolizers

Roughly 2-5% of white adults and up to 15-20% of East Asian adults are CYP2C19 poor metabolizers, meaning omeprazole plasma concentrations may be 3-5 times higher than in extensive metabolizers. This does not create an NMN/NR interaction. It does mean poor metabolizers get stronger acid suppression from the same omeprazole dose, which could theoretically amplify any pH-related effect on NMN dissolution. The practical impact remains unquantified.

Older Adults

Adults over 65 are the most likely to use both long-term PPIs and NAD+ precursor supplements for healthy aging. PPI prescriptions in adults 65 and older exceed 25 million annually in the US according to CMS Part D data. This is also the population in which NAD+ decline is most pronounced. The lack of a known pharmacokinetic interaction is reassuring for this group, though the B12/magnesium monitoring note above applies with added urgency.

Pregnancy and Lactation

No safety data exists for NMN or NR in pregnancy. Neither omeprazole nor pantoprazole is categorically contraindicated in pregnancy, with omeprazole FDA Pregnancy Category C and pantoprazole Category B under the old system. Pregnant patients should not take NMN or NR without direct physician guidance regardless of PPI status.

What Clinicians Should Document and Monitor

Even low-risk supplement-drug combinations warrant a note in the chart. For a patient taking NMN or NR with a PPI:

• Document the NMN or NR dose and brand in the medication reconciliation list.
• Note the PPI dose, duration of use, and indication.
• If PPI use exceeds 12 months, check serum B12, serum magnesium, and a basic metabolic panel per standard long-term PPI monitoring guidelines from the American Gastroenterological Association.
• No NMN- or NR-specific labs are required to monitor for this combination.
• Reassess PPI indication at each visit. The AGA guideline published in Gastroenterology (2017) notes that "PPIs are frequently prescribed without a clear indication and should be deprescribed when the clinical rationale no longer exists."

Summary of Interaction Classification

By standard DDI classification criteria used in clinical pharmacology (mechanistic plausibility, in vitro data, clinical case reports, controlled trials), the NMN/NR-PPI combination falls into the following category:

No clinically significant interaction identified. Theoretical class D concern (possible pH-mediated dissolution alteration for NMN) lacks supporting clinical evidence and can be managed by simple timing.

The FDA Adverse Event Reporting System (FAERS) contains no case reports as of the 2024 quarterly release linking NMN or NR with adverse events attributed to PPI co-administration.